Cantor Fitzgerald Comments on ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for ALX Oncology in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($2.21) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

A number of other equities analysts have also weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group downgraded ALX Oncology from a “buy” rating to a “hold” rating and dropped their price target for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, ALX Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

ALX Oncology Trading Down 22.5 %

Shares of ALX Oncology stock opened at $1.40 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The company has a fifty day moving average of $1.61 and a 200 day moving average of $2.43. The company has a market capitalization of $73.57 million, a P/E ratio of -0.45 and a beta of 0.98. ALX Oncology has a fifty-two week low of $1.19 and a fifty-two week high of $17.83.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new stake in ALX Oncology in the 2nd quarter worth approximately $63,000. AQR Capital Management LLC boosted its holdings in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after buying an additional 6,080 shares in the last quarter. SG Americas Securities LLC grew its position in ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares during the period. Algert Global LLC purchased a new position in ALX Oncology in the second quarter valued at $249,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of ALX Oncology during the 3rd quarter worth about $88,000. 97.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Rekha Hemrajani acquired 30,000 shares of ALX Oncology stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. This represents a 1,000.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 14,443 shares of company stock valued at $23,309. Company insiders own 33.40% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.